Schedule 13D ownership disclosure

Edgewise Therapeutics Inc

Common Stock · CUSIP: 28036F105

Event date: 2025-05-09

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • ORBIMED ADVISORS LLCReported CIK 0001055951

    Shares: 15,252,867.00 · Class: 14.5%

  • ORBIMED CAPITAL GP VI LLCReported CIK 0001682115

    Shares: 14,809,075.00 · Class: 14.1%

  • OrbiMed Genesis GP LLCReported CIK 0001808744

    Shares: 443,792.00 · Class: 0.4%

  • ORBIMED CAPITAL LLCReported CIK 0001157524

    Shares: 265,625.00 · Class: 0.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000947871-25-000490
Form type
SCHEDULE 13D/A
Filer
Edgewise Therapeutics, Inc.
CIK
CIK 1710072
Filed
May 12, 2025
Reporting period
May 09, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub